Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells

Cancer Letters

Volumn 237, Issue 2, 2006, Pages 223-233

  Iguchi, Kazuhiro ^a   Nakano, Toru ^a   Usui, Shigeyuki ^a   Hirano, Kazuyuki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Incadronate; Mevalonate pathway; PC 3 cells; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GERANYLGERANYL PYROPHOSPHATE; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCADRONIC ACID; ISOPRENOID; MESSENGER RNA; MEVALONIC ACID; MICROSOMAL AMINOPEPTIDASE; PARVASTATIN; RAP1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CANCER CELL; CELL MEMBRANE; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

ANTIGENS, CD13; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSOL; DIPHOSPHONATES; ENZYME INHIBITORS; HUMANS; LEUCINE; MALE; MEVALONIC ACID; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RAP1 GTP-BINDING PROTEINS;

EID: 33646827825     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.006     Document Type: Article

References (45)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J. Clin. 54 (2004) 8-29
2. Carlin B.I., and Andriole G.L. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88 (2000) 2989-2994
3. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 35 (2004) 1655-1664
4. Charhon S.A., Chapuy M.C., Delvin E.E., Valentin-Opran A., Edouard C.M., and Meunier P.J. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51 (1983) 918-924
5. Urwin G.H., Percival R.C., Harris S., Beneton M.N., Williams J.L., and Kanis J.A. Generalised increase in bone resorption in carcinoma of the prostate. Br. J. Urol. 57 (1985) 721-723
6. Percival R.C., Urwin G.H., Harris S., Yates A.J., Williams J.L., Beneton M., and Kanis J.A. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur. J. Surg. Oncol. 13 (1987) 41-49
7. Fleisch H. Bisphosphonates: mechanisms of action. Endocr. Rev. 19 (1998) 80-100
8. Francis M.D., Russell R.G., and Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165 (1969) 1264-1266
9. Jung A., Bornand J., Mermillod B., Edouard C., and Meunier P.J. Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res. 44 (1984) 3007-3011
10. Jung A., Mermillod B., Barras C., Baud M., and Courvoisier B. Inhibition by two diphosphonates of bone lysis in tumor-conditioned media. Cancer Res. 41 (1981) 3233-3237
11. Body J.J., and Dumon J.C. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Ann. Oncol. 5 (1994) 359-363
12. Sasaki A., Boyce B.F., Story B., Wright K.R., Chapman M., Boyce R., et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55 (1995) 3551-3557
13. Adami S., Salvagno G., Guarrera G., Bianchi G., Dorizzi R., Rosini S., et al. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J. Urol. 134 (1985) 1152-1154
14. Lahtinen R., Laakso M., Palva I., Virkkunen P., and Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340 (1992) 1049-1052
15. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334 (1996) 488-493
16. Hortobagyi G.N., Theriault R.L., Porter L., Blayney D., Lipton A., Sinoff C., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335 (1996) 1785-1791
17. Diel I.J., Solomayer E.F., Costa S.D., Gollan C., Goerner R., Wallwiener D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339 (1998) 357-363
18. Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F.H., Delmas P.D., and Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57 (1997) 3890-3894
19. Virtanen S.S., Vaananen H.K., Harkonen P.L., and Lakkakorpi P.T. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 62 (2002) 2708-2714
20. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60 (2000) 2949-2954
21. Derenne S., Amiot M., Barille S., Collette M., Robillard N., Berthaud P., et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner. Res. 14 (1999) 2048-2056
22. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., and Colston K.W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82 (2000) 1459-1468
23. Oades G.M., Senaratne S.G., Clarke I.A., Kirby R.S., and Colston K.W. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J. Urol. 170 (2003) 246-252
24. Lee M.V., Fong E.M., Singer F.R., and Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61 (2001) 2602-2608
25. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13 (1998) 581-589
26. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264 (1999) 108-111
27. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2001) 235-242
28. Szabo C.M., Matsumura Y., Fukura S., Martin M.B., Sanders J.M., Sengupta S., et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J. Med. Chem. 45 (2002) 2185-2196
29. Seabra M.C. Membrane association and targeting of prenylated Ras-like GTPases. Cell Signal. 10 (1998) 167-172
30. Takai Y., Sasaki T., and Matozaki T. Small GTP-binding proteins. Physiol. Rev. 81 (2001) 153-208
31. Saiki I., Fujii H., Yoneda J., Abe F., Nakajima M., Tsuruo T., and Azuma I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int. J. Cancer 54 (1993) 137-143
32. Ishii K., Usui S., Sugimura Y., Yamamoto H., Yoshikawa K., and Hirano K. Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells. Biol. Pharm. Bull. 24 (2001) 226-230
33. Ishii K., Usui S., Sugimura Y., Yoshida S., Hioki T., Tatematsu M., et al. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int. J. Cancer 92 (2001) 49-54
34. Iguchi K., Hamatake M., Ishida R., Usami Y., Adachi T., Yamamoto H., et al. Induction of necrosis by zinc in prostate carcinoma cells and identification of proteins increased in association with this induction. Eur. J. Biochem. 253 (1998) 766-770
35. Bhagwat S.V., Petrovic N., Okamoto Y., and Shapiro L.H. The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood 101 (2003) 1818-1826
36. Hare J.F. Mechanisms of membrane protein turnover. Biochim. Biophys. Acta 1031 (1990) 71-90
37. Kido A., Krueger S., Haeckel C., and Roessner A. Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells. Clin. Exp. Metastasis 20 (2003) 585-592
38. Bhagwat S.V., Lahdenranta J., Giordano R., Arap W., Pasqualini R., and Shapiro L.H. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97 (2001) 652-659
39. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60 (2000) 722-727
40. Blomgren H., Strender L.E., and Edsmyr F. Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator, a phase I study. Biomedicine 32 (1980) 178-185
41. Hashida H., Takabayashi A., Kanai M., Adachi M., Kondo K., Kohno N., et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 122 (2002) 376-386
42. Favaloro E.J., Browning T., Nandurkar H., Sartor M., Bradstock K.F., and Koutts J. Aminopeptidase-N (CD13; gp 150): contrasting patterns of enzymatic activity in blood from patients with myeloid or lymphoid leukemia. Leuk. Res. 19 (1995) 659-666
43. Ikeda N., Nakajima Y., Tokuhara T., Hattori N., Sho M., Kanehiro H., and Miyake M. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin. Cancer Res. 9 (2003) 1503-1508
44. Ichinose Y., Genka K., Koike T., Kato H., Watanabe Y., Mori T., et al. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J. Natl. Cancer Inst. 95 (2003) 605-610
45. Ota K., and Ogawa N. Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults. Biomed. Pharmacother. 44 (1990) 93-101